{"id":68,"date":"2014-08-19T09:36:37","date_gmt":"2014-08-19T09:36:37","guid":{"rendered":"http:\/\/delveinsightblog.wordpress.com\/2014\/08\/19\/metastatic-prostate-cancer-pipeline-insights-2014\/"},"modified":"2025-05-02T16:23:15","modified_gmt":"2025-05-02T10:53:15","slug":"metastatic-prostate-cancer-pipeline-insights-2014","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/metastatic-prostate-cancer-pipeline-insights-2014","title":{"rendered":"Metastatic Prostate Cancer-Pipeline Insights, 2014"},"content":{"rendered":"

The \u201c Metastatic Prostate Cancer-Pipeline Insights, 2014<\/strong><\/span>\u201d, report by DelveInsight<\/strong> <\/a>provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Prostate Cancer. This report provides information on the therapeutic development based on the Metastatic Prostate Cancer dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.<\/p>\n

Scope<\/span><\/strong>
\n– The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer
\n– The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
\n– Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
\n– The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and also provide company profiling
\n– The report also gives the information of dormant and discontinued pipeline projects
\n– Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
\n– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type<\/p>\n

Reasons to buy<\/span><\/strong>
\n– Complete Pipeline intelligence and complete understanding over therapeutics development for Metastatic Prostate Cancer
\n– Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
\n– Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics
\n– Developing strategic initiatives to support your drug development activities.
\n– Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
\n– Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
\n– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
\n– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
\n– Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions<\/p>\n

Table of Contents<\/span><\/strong>
\n– Metastatic Prostate Cancer Overview
\n– Metastatic Prostate Cancer Pipeline Therapeutics
\n– Metastatic Prostate Cancer Therapeutics under Development by Companies
\n– Metastatic Prostate Cancer Late Stage Products (Filed and Phase III)
\n– Comparative Analysis
\n– Metastatic Prostate Cancer Mid Clinical Stage Products (Phase II)
\n– Comparative Analysis
\n– Metastatic Prostate Cancer Early Clinical Stage Products (Phase I and IND Filed)
\n– Comparative Analysis
\n– Metastatic Prostate Cancer Discovery and Pre-Clinical Stage Products
\n– Comparative Analysis
\n– Drug Candidate Profiles
\n– Metastatic Prostate Cancer – Therapeutics Assessment
\n– Assessment by Monotherapy Products
\n– Assessment by Combination Products
\n– Assessment by Route of Administration
\n– Assessment by Molecule Type
\n– Metastatic Prostate Cancer – Discontinued Products
\n– Metastatic Prostate Cancer – Dormant Products
\n– Companies Involved in Therapeutics Development for Metastatic Prostate Cancer
\n– Appendix
\n– Methodology
\n– Contact Us
\n– Disclaimer<\/p>\n

List of Tables<\/span><\/strong><\/p>\n

– Number of Products under Development for Metastatic Prostate Cancer, 2014
\n– Number of Products under Development by Companies
\n– Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
\n– Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
\n– Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
\n– Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
\n– Drug Candidates Profiles
\n– Metastatic Prostate Cancer Assessment by Monotherapy Products
\n– Metastatic Prostate Cancer Assessment by Combination Products
\n– Metastatic Prostate Cancer Assessment by Route of Administration
\n– Metastatic Prostate Cancer Assessment by Stage and Route of Administration
\n– Metastatic Prostate Cancer Assessment by Molecule Type
\n– Metastatic Prostate Cancer Assessment by Stage and Molecule Type
\n– Metastatic Prostate Cancer Therapeutics – Discontinued Products
\n– Metastatic Prostate Cancer Therapeutics – Dormant Products
\n– Products under Development by Companies, 2014<\/p>\n

List of Figures<\/strong><\/span><\/p>\n

– Number of Products under Development for Metastatic Prostate Cancer, 2014
\n– Late Clinical Stage Products (Filed and Phase III), 2014
\n– Mid Clinical Stage Products (Phase II), 2014
\n– Early Clinical Stage Products (Phase I and IND Filed), 2014
\n– Discovery and Pre-Clinical Stage Products, 2014
\n– Metastatic Prostate Cancer Assessment by Monotherapy Products
\n– Metastatic Prostate Cancer Assessment by Combination Products
\n– Metastatic Prostate Cancer Assessment by Route of Administration
\n– Metastatic Prostate Cancer Assessment by Stage and Route of Administration
\n– Metastatic Prostate Cancer Assessment by Molecule Type
\n– Metastatic Prostate Cancer Assessment by Stage and Molecule Type<\/p>\n

Report Pricing<\/span><\/strong>
\nSingle User License: $1250
\nSite License:$2500
\nGlobal License:$4000<\/p>\n

For Sample Pages and Report, please contact us at info@delveinsight.com<\/p>\n","protected":false},"excerpt":{"rendered":"

The \u201c Metastatic Prostate Cancer-Pipeline Insights, 2014\u201d, report by DelveInsight provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Prostate Cancer. This report provides information on the therapeutic development based on the Metastatic Prostate Cancer […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[134,178,179,204,213,216,246,261,319,322,399,402,407,463,464,465,466,472,473,474,476,481,492,508,509,511,512,556,566,567,569,576,578,579],"industry":[17225],"therapeutic_areas":[17230,17228],"class_list":["post-68","post","type-post","status-publish","format-standard","hentry","category-articles","tag-business-consultant","tag-company-overview","tag-company-profiling","tag-delveinsight","tag-discovery","tag-drug","tag-filed","tag-generic-companies","tag-ind-filed","tag-indication","tag-metastatic-prostate-cancer","tag-moa","tag-monotherapy","tag-pharm-insights","tag-pharma","tag-pharma-companies","tag-pharma-company","tag-phase-i","tag-phase-ii","tag-phase-iii","tag-phase-iii-pipeline","tag-pipeline-drugs","tag-preclinical","tag-report-buyers","tag-report-linker","tag-report-stack","tag-reports","tag-targets","tag-therapeutic-area","tag-therapeutic-development","tag-therapeutics","tag-top-10-companies","tag-top-10-oncology-drugs","tag-track-your-closest-competitors","industry-pharmaceutical","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nMetastatic Prostate Cancer Pipeline Analysis | Metastatic Prostate Cancer<\/title>\n<meta name=\"description\" content=\"DelveInsight\u2019s, Metastatic Prostate Cancer Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/metastatic-prostate-cancer-pipeline-insights-2014\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Metastatic Prostate Cancer Pipeline Analysis | Metastatic Prostate Cancer\" \/>\n<meta property=\"og:description\" content=\"DelveInsight\u2019s, Metastatic Prostate Cancer Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/metastatic-prostate-cancer-pipeline-insights-2014\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-19T09:36:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-02T10:53:15+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Metastatic Prostate Cancer Pipeline Analysis | Metastatic Prostate Cancer","description":"DelveInsight\u2019s, Metastatic Prostate Cancer Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/metastatic-prostate-cancer-pipeline-insights-2014","og_locale":"en_US","og_type":"article","og_title":"Metastatic Prostate Cancer Pipeline Analysis | Metastatic Prostate Cancer","og_description":"DelveInsight\u2019s, Metastatic Prostate Cancer Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication....","og_url":"https:\/\/www.delveinsight.com\/blog\/metastatic-prostate-cancer-pipeline-insights-2014","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2014-08-19T09:36:37+00:00","article_modified_time":"2025-05-02T10:53:15+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/metastatic-prostate-cancer-pipeline-insights-2014","url":"https:\/\/www.delveinsight.com\/blog\/metastatic-prostate-cancer-pipeline-insights-2014","name":"Metastatic Prostate Cancer Pipeline Analysis | Metastatic Prostate Cancer","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2014-08-19T09:36:37+00:00","dateModified":"2025-05-02T10:53:15+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"DelveInsight\u2019s, Metastatic Prostate Cancer Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/metastatic-prostate-cancer-pipeline-insights-2014"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Company Overview<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">company profiling<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Discovery<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Filed<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Generic Companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IND filed<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Indication<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Metastatic Prostate Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">MOA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">monotherapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharm Insights<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharma Companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharma Company<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Phase I<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Phase II<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Phase III<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Phase III Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Preclinical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Report Buyers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Report Linker<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Report Stack<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">targets<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">therapeutic Area<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">therapeutic development<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Top 10 Companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Top 10 Oncology Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Track your closest Competitors<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">Company Overview<\/span>","<span class=\"advgb-post-tax-term\">company profiling<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Discovery<\/span>","<span class=\"advgb-post-tax-term\">Drug<\/span>","<span class=\"advgb-post-tax-term\">Filed<\/span>","<span class=\"advgb-post-tax-term\">Generic Companies<\/span>","<span class=\"advgb-post-tax-term\">IND filed<\/span>","<span class=\"advgb-post-tax-term\">Indication<\/span>","<span class=\"advgb-post-tax-term\">Metastatic Prostate Cancer<\/span>","<span class=\"advgb-post-tax-term\">MOA<\/span>","<span class=\"advgb-post-tax-term\">monotherapy<\/span>","<span class=\"advgb-post-tax-term\">Pharm Insights<\/span>","<span class=\"advgb-post-tax-term\">Pharma<\/span>","<span class=\"advgb-post-tax-term\">Pharma Companies<\/span>","<span class=\"advgb-post-tax-term\">Pharma Company<\/span>","<span class=\"advgb-post-tax-term\">Phase I<\/span>","<span class=\"advgb-post-tax-term\">Phase II<\/span>","<span class=\"advgb-post-tax-term\">Phase III<\/span>","<span class=\"advgb-post-tax-term\">Phase III Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Pipeline Drugs<\/span>","<span class=\"advgb-post-tax-term\">Preclinical<\/span>","<span class=\"advgb-post-tax-term\">Report Buyers<\/span>","<span class=\"advgb-post-tax-term\">Report Linker<\/span>","<span class=\"advgb-post-tax-term\">Report Stack<\/span>","<span class=\"advgb-post-tax-term\">Reports<\/span>","<span class=\"advgb-post-tax-term\">targets<\/span>","<span class=\"advgb-post-tax-term\">therapeutic Area<\/span>","<span class=\"advgb-post-tax-term\">therapeutic development<\/span>","<span class=\"advgb-post-tax-term\">therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Top 10 Companies<\/span>","<span class=\"advgb-post-tax-term\">Top 10 Oncology Drugs<\/span>","<span class=\"advgb-post-tax-term\">Track your closest Competitors<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 12 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Aug 19, 2014","modified":"Updated on May 2, 2025"},"absolute_dates_time":{"created":"Posted on Aug 19, 2014 9:36 am","modified":"Updated on May 2, 2025 4:23 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/68","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=68"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/68\/revisions"}],"predecessor-version":[{"id":31598,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/68\/revisions\/31598"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=68"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=68"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=68"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=68"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=68"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}